226 related articles for article (PubMed ID: 12787563)
1. Biology of the TRANCE axis.
Walsh MC; Choi Y
Cytokine Growth Factor Rev; 2003; 14(3-4):251-63. PubMed ID: 12787563
[TBL] [Abstract][Full Text] [Related]
2. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.
Takahashi N; Udagawa N; Suda T
Biochem Biophys Res Commun; 1999 Mar; 256(3):449-55. PubMed ID: 10080918
[TBL] [Abstract][Full Text] [Related]
3. The role of TNF-related activation-induced cytokine-receptor activating NF-kappa B interaction in acute allograft rejection and CD40L-independent chronic allograft rejection.
Guillonneau C; Louvet C; Renaudin K; Heslan JM; Heslan M; Tesson L; Vignes C; Guillot C; Choi Y; Turka LA; Cuturi MC; Anegon I; Josien R
J Immunol; 2004 Feb; 172(3):1619-29. PubMed ID: 14734743
[TBL] [Abstract][Full Text] [Related]
4. Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo.
Cheng X; Kinosaki M; Takami M; Choi Y; Zhang H; Murali R
J Biol Chem; 2004 Feb; 279(9):8269-77. PubMed ID: 14679212
[TBL] [Abstract][Full Text] [Related]
5. Role of RANKL and RANK in bone loss and arthritis.
Jones DH; Kong YY; Penninger JM
Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii32-9. PubMed ID: 12379618
[TBL] [Abstract][Full Text] [Related]
6. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
Ikeda T; Utsuyama M; Hirokawa K
J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
[TBL] [Abstract][Full Text] [Related]
7. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function.
Wong BR; Josien R; Choi Y
J Leukoc Biol; 1999 Jun; 65(6):715-24. PubMed ID: 10380891
[TBL] [Abstract][Full Text] [Related]
8. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function.
Schoppet M; Preissner KT; Hofbauer LC
Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):549-53. PubMed ID: 11950689
[TBL] [Abstract][Full Text] [Related]
9. RANK-L and RANK: T cells, bone loss, and mammalian evolution.
Theill LE; Boyle WJ; Penninger JM
Annu Rev Immunol; 2002; 20():795-823. PubMed ID: 11861618
[TBL] [Abstract][Full Text] [Related]
10. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
Lee SK; Lorenzo JA
Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
[TBL] [Abstract][Full Text] [Related]
11. The TNF receptor superfamily: role in immune inflammation and bone formation.
Cheng X; Kinosaki M; Murali R; Greene MI
Immunol Res; 2003; 27(2-3):287-94. PubMed ID: 12857975
[TBL] [Abstract][Full Text] [Related]
12. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint.
Haynes DR; Crotti TN; Loric M; Bain GI; Atkins GJ; Findlay DM
Rheumatology (Oxford); 2001 Jun; 40(6):623-30. PubMed ID: 11426018
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development.
Kong YY; Boyle WJ; Penninger JM
Immunol Cell Biol; 1999 Apr; 77(2):188-93. PubMed ID: 10234557
[TBL] [Abstract][Full Text] [Related]
14. RANKL and RANK as novel therapeutic targets for arthritis.
Nakashima T; Wada T; Penninger JM
Curr Opin Rheumatol; 2003 May; 15(3):280-7. PubMed ID: 12707582
[TBL] [Abstract][Full Text] [Related]
15. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors.
Atkins GJ; Haynes DR; Graves SE; Evdokiou A; Hay S; Bouralexis S; Findlay DM
J Bone Miner Res; 2000 Apr; 15(4):640-9. PubMed ID: 10780856
[TBL] [Abstract][Full Text] [Related]
16. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
17. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
Hofbauer LC; Heufelder AE
J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.
Kostenuik PJ; Shalhoub V
Curr Pharm Des; 2001 May; 7(8):613-35. PubMed ID: 11375772
[TBL] [Abstract][Full Text] [Related]
19. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.
Huang L; Xu J; Wood DJ; Zheng MH
Am J Pathol; 2000 Mar; 156(3):761-7. PubMed ID: 10702390
[TBL] [Abstract][Full Text] [Related]
20. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
Collin-Osdoby P
Circ Res; 2004 Nov; 95(11):1046-57. PubMed ID: 15564564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
